Import from '@/components'

Can I Take 5-HTP with Leqvio (Inclisiran)?

What Is Inclisiran and Why Are Women Prescribed It?

Inclisiran (Leqvio) is a small interfering RNA (siRNA) therapy that silences the gene encoding PCSK9 in the liver, causing LDL receptors to stay on cell surfaces longer and pull more LDL-cholesterol out of circulation. The FDA approved inclisiran in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering on top of maximally tolerated statin therapy.

Women are prescribed inclisiran for the same indications as men, but the cardiovascular context is different by sex.

How Female Cardiovascular Risk Changes Across the Lifespan

Estrogen has well-documented atheroprotective effects during the reproductive years. After natural menopause, LDL-cholesterol typically rises by 10-15 percent, triglycerides increase, and HDL-cholesterol shifts unfavorably. The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease explicitly lists premature menopause (before age 40) as a risk-enhancing factor that should prompt earlier, more aggressive lipid management. Women with premature ovarian insufficiency or surgical menopause therefore reach the threshold for PCSK9-inhibitor consideration at a younger age than population averages suggest.

Women with PCOS also carry a disproportionate lipid burden. A meta-analysis published in Human Reproduction Update found that women with PCOS have significantly higher LDL-cholesterol and triglycerides compared with age-matched controls, a pattern that persists after adjusting for BMI. If you have PCOS and familial hypercholesterolemia, you may be a candidate for aggressive lipid-lowering therapy earlier in life than your peers.

Inclisiran's Mechanism: Why the Interaction Picture Is Unusual

Inclisiran does not travel through the same metabolic pathways as most drugs. It is taken up almost entirely by the liver via the ASGPR receptor and does not circulate systemically at meaningful concentrations after the first 48 hours. Phase 1 pharmacokinetic data from the ORION-1 trial showed that inclisiran is rapidly cleared from plasma, does not inhibit or induce CYP450 enzymes, is not a substrate of major drug transporters (P-gp, BCRP), and has no significant plasma-protein binding interactions. This is a fundamentally different profile from statins, which are CYP3A4 or OATP1B substrates.

The practical implication: most classic pharmacokinetic drug-drug interactions simply do not apply to inclisiran. What matters instead is any pharmacodynamic overlap between inclisiran's co-medications and whatever supplements you are adding.

What Is 5-HTP and Why Do Women Take It?

5-Hydroxytryptophan (5-HTP) is a naturally occurring amino acid and the immediate precursor to serotonin. It crosses the blood-brain barrier and is converted to serotonin in the central nervous system. Sold without a prescription in the United States, 5-HTP is marketed primarily for mood support, sleep, appetite control, and migraine prevention.

Women use 5-HTP at higher rates than men, and for reasons tied directly to hormonal biology. Serotonin synthesis in women is approximately 52 percent lower than in men under baseline conditions, according to a PET imaging study by Nishizawa and colleagues. Estrogen upregulates tryptophan hydroxylase (the enzyme that makes serotonin) and also modulates serotonin reuptake transporter expression, so serotonin availability fluctuates across the menstrual cycle, spikes in postpartum estrogen withdrawal, and declines in perimenopause.

Life-Stage Reasons Women Reach for 5-HTP

Perimenopause and post-menopause. Hot flashes, poor sleep, and mood changes drive many women toward 5-HTP in midlife. This is also the life stage at which Leqvio is most commonly prescribed. The overlap is real and clinically relevant.

Premenstrual dysphoric disorder (PMDD) and PMS. Lower serotonergic tone in the luteal phase is a core feature of PMDD. Some women self-treat with 5-HTP rather than, or alongside, prescribed SSRIs. If you are one of them, the serotonin-load question below becomes especially important.

Postpartum mood support. Women in the postpartum period sometimes reach for 5-HTP before seeking a prescription. Leqvio use in the postpartum period would be unusual, but the interaction with breastfeeding matters (see the pregnancy and lactation section below).

Appetite and weight management. A randomized controlled trial by Cangiano et al. found that 5-HTP at 900 mg/day reduced carbohydrate intake and produced greater weight loss than placebo in women with obesity over 12 weeks. Some women with PCOS or metabolic syndrome use 5-HTP for this reason, and these are the same women who may also have dyslipidemia requiring Leqvio.

The Core Question: Does 5-HTP Interact with Inclisiran?

The direct answer is that no published study, case report, or regulatory document has identified a pharmacokinetic interaction between 5-HTP and inclisiran. The absence of CYP450 involvement on inclisiran's side and the primarily CNS-directed action of 5-HTP mean these two agents do not compete for the same enzymes, transporters, or plasma-protein binding sites.

The real concern is two levels removed, and it matters a great deal.

The Indirect Serotonin Syndrome Pathway

Inclisiran itself has no serotonergic activity. The risk equation changes when you look at the full medication list of a woman who is prescribed Leqvio. Many women in the perimenopausal and postmenopausal age group who qualify for inclisiran are also taking:

• An SSRI or SNRI (for depression, anxiety, hot flash reduction, or PMDD)
• Tramadol (for pain, which has serotonin-reuptake inhibiting properties)
• Triptans (for migraine)
• Linezolid or certain antivirals (rare but relevant)

5-HTP raises serotonergic tone by flooding the synthesis pathway with substrate. Adding 5-HTP to an SSRI or SNRI can, in some individuals, tip the balance toward serotonin syndrome. A 2018 narrative review in the Journal of Pharmacy Practice catalogued reported cases of serotonin syndrome involving 5-HTP and serotonergic drugs, noting that the risk is dose-dependent and accelerated by rapid dose escalation of either agent.

So the interaction chain looks like this:

Leqvio (no serotonergic effect) + SSRI/SNRI or other serotonergic co-medication (prescribed) + 5-HTP (supplement) = potential serotonin overload.

Inclisiran is the bystander in this equation, but the woman taking it may be the one who experiences the harm. Prescribers sometimes review only the drug-drug interaction list and miss the supplement-drug piece entirely.

Recognizing Serotonin Syndrome

Serotonin syndrome ranges from mild to life-threatening. Early signs include agitation, restlessness, rapid heart rate, sweating, dilated pupils, and muscle twitching (clonus). Severe presentations include hyperthermia, seizures, and rhabdomyolysis. The Hunter Criteria are the validated clinical decision tool: clonus (spontaneous, inducible, or ocular) is the most specific finding.

If you develop any of these symptoms after starting 5-HTP in the context of a serotonergic medication, stop the supplement and contact your provider the same day. Severe symptoms require emergency evaluation.

Is the Risk the Same Across All Doses of 5-HTP?

No meaningful dose-response data exist specifically for 5-HTP-related serotonin syndrome in the context of concurrent SSRIs, because such studies cannot be ethically conducted. What is known from pharmacology is that risk scales with the total serotonergic burden. Lower doses of 5-HTP (50-100 mg/day) carry less theoretical risk than the 300-900 mg/day doses used in some weight-management or migraine trials. This is not a green light for low doses when serotonergic drugs are present. It is a statement about relative rather than absolute risk.

The WomanRx editorial team proposes a practical three-tier framework for women considering 5-HTP alongside Leqvio:

Tier 1 (Lower concern): You take Leqvio and no serotonergic co-medication. The direct inclisiran-5-HTP interaction risk is negligible based on current evidence. Discuss with your prescriber, and document the supplement in your chart.

Tier 2 (Moderate concern): You take Leqvio plus a serotonergic drug (SSRI, SNRI, triptan, tramadol). Adding 5-HTP raises your total serotonergic burden. This combination warrants an explicit discussion with your prescriber before starting 5-HTP. A conservative approach is to avoid 5-HTP entirely in this tier and address the underlying symptom (sleep, mood, appetite) through evidence-based alternatives.

Tier 3 (High concern): You take Leqvio plus a serotonergic drug and are considering high-dose 5-HTP (above 200 mg/day). This combination should not be initiated without prescriber involvement and a plan for monitoring symptoms.

Pharmacokinetics in Women: What Changes the Calculation

Sex differences in pharmacokinetics are real and often under-studied. Inclisiran's clinical trials included women, but sex-stratified pharmacokinetic data are not published in detail in the primary ORION trial papers. The ORION-10 trial, which enrolled patients with ASCVD, showed that inclisiran reduced LDL-cholesterol by approximately 52 percent from baseline at month 17 in the overall population. Whether women achieved a different magnitude of response is not reported separately in the primary paper, a gap that reflects a persistent problem in cardiovascular trial reporting.

For 5-HTP, sex differences in serotonin synthesis and reuptake mean that women may be more sensitive to changes in serotonergic tone, not less. Lower baseline serotonin synthesis rates in women mean that exogenous 5-HTP may produce a proportionally larger serotonergic effect per milligram than in men. This adds a layer of caution that is specific to women and not captured in most general drug interaction resources.

Pregnancy, Lactation, and Contraception

Inclisiran is contraindicated in pregnancy. The FDA label carries an explicit contraindication. Animal reproduction studies showed adverse fetal effects at doses producing systemic exposures below the human therapeutic dose. There are no adequate human data on inclisiran use during pregnancy.

Because inclisiran is dosed every six months after the loading phase, you must discontinue therapy and use reliable contraception before attempting conception. The prescribing information does not specify a required washout interval before conception, but the every-six-month dosing schedule means a dose administered in Month 1 continues to suppress hepatic PCSK9 mRNA through at least Month 6. Discuss with your reproductive endocrinologist or OB-GYN the timing of discontinuation relative to your conception attempt.

Lactation: There are no human data on inclisiran excretion in breast milk. Given the absence of safety data and the non-urgent nature of LDL lowering in the short term, most clinicians advise against using inclisiran while breastfeeding. Statins, the more common lipid-lowering agents, are also contraindicated during lactation.

5-HTP in pregnancy: No controlled human studies exist. Animal data show adverse fetal effects at high doses. The Natural Medicines database rates 5-HTP as "Possibly Unsafe" in pregnancy. Avoid during pregnancy and, given the unknown lactation transfer, also during breastfeeding.

Contraception note: If you are of reproductive age and are prescribed inclisiran, you need effective contraception throughout therapy. Discuss your contraceptive options with your prescriber. Combined hormonal contraceptives have modest effects on lipid panels (some raise triglycerides, some raise LDL slightly depending on the progestin), which is relevant context when monitoring lipid response to inclisiran.

Who This Is Right For and Who Should Reconsider

Women Who Can Likely Use 5-HTP Without Inclisiran-Specific Concern

• Postmenopausal women on Leqvio who are not taking any serotonergic medication and whose complete medication list has been reviewed by their prescriber.
• Women using low-dose 5-HTP (50 mg, once nightly for sleep) with no serotonergic co-medications.

Women Who Should Discuss This Carefully Before Combining

• Perimenopausal or postmenopausal women on both an SSRI (for hot flash or mood management) and Leqvio who are considering adding 5-HTP.
• Women with PCOS-related depression or anxiety who are on an SNRI and are prescribed Leqvio for early-onset dyslipidemia.
• Women who self-treat PMDD with 5-HTP and have recently been started on inclisiran for a familial hypercholesterolemia diagnosis.

Women Who Should Avoid the Combination Without Specialist Input

• Women on high-dose SSRIs or on a combination of two serotonergic agents (for example, an SSRI plus tramadol for chronic pain).
• Women on venlafaxine for hot flash management alongside Leqvio, who are considering adding 5-HTP for sleep or appetite.

What to Tell Your Prescriber

Bring a written list of every supplement, including dose and frequency, to your next Leqvio injection appointment. Many prescribers work in clinical settings where injection appointments are brief. A written list takes the burden off the conversation and gets documented in your chart.

Specifically ask: "I am taking [or considering taking] 5-HTP at [dose] for [reason]. Are there any other medications I am currently prescribed that would make this a concern?"

If your provider is not familiar with 5-HTP's serotonergic mechanism, you can reference the pharmacology section of the NIH LiverTox database entry for serotonin syndrome as a starting point for that discussion.

Monitoring Your LDL Response on Inclisiran

The ORION-9 trial, which specifically enrolled patients with heterozygous familial hypercholesterolemia, showed a 39.7 percent placebo-corrected reduction in LDL-cholesterol at Day 510. Women with FH have a significantly elevated lifetime cardiovascular risk, and the long injection interval every six months improves adherence compared with daily oral alternatives.

Standard monitoring while on inclisiran includes a fasting lipid panel before each injection to confirm ongoing LDL suppression, and liver function tests at baseline and periodically as clinically indicated. No specific 5-HTP-related lab monitoring exists for the inclisiran interaction question, but if you are also on a serotonergic medication, ask your provider whether any metabolic markers (such as platelet serotonin level or creatine kinase if myopathy symptoms appear) warrant periodic checks.

Evidence Gaps Specific to Women

Women have been systematically under-represented in cardiovascular outcomes trials. A 2020 analysis in the Journal of the American Heart Association found that women comprised only 38 percent of participants in major cardiovascular trials between 2010 and 2017, and sex-stratified efficacy data were reported in fewer than half. The ORION trial program enrolled a meaningful proportion of women but did not publish sex-stratified pharmacokinetic or efficacy subgroup analyses as primary outcomes.

For 5-HTP specifically, the Nishizawa serotonin synthesis study is the foundational paper establishing lower female serotonin synthesis rates, but it dates to 1997 and has not been replicated at scale. The implication that women might experience larger per-dose serotonergic effects from 5-HTP is pharmacologically plausible but not confirmed in controlled trials. When you read a resource that says "5-HTP is generally safe," recognize that the evidence base is built primarily on short-term trials with small samples, and women-specific dose-response data are essentially absent.

Being honest about that gap is more useful to you than false reassurance.